The effect of esketamine in patients with treatment‐resistant depression with and without comorbid anxiety symptoms or disorder
E. Daly, Ibrahim Turkoz, Giacomo Salvadore, Maggie Fedgchin, Dawn F. Ionescu, H. Starr, Stephane Borentain, Madhukar H. Trivedi, Michael E. Thase, Jaskaran Singh
Depression and Anxiety July 22, 2021 DOI: 10.1002/da.23193 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Post hoc analysis Peer reviewed |
|---|---|
| Population | Patients with treatment-resistant depression with or without comorbid anxiety |
| Interventions | Esketamine antidepressant |
| Topics | Anxiety Depression Esketamine |
| Key points | Esketamine plus an antidepressant improved depressive symptoms more than an antidepressant alone in treatment-resistant depression patients with comorbid anxiety. |
Abstract
Comorbid anxiety is generally associated with poorer response to antidepressant treatment. This post hoc analysis explored the efficacy of esketamine plus an antidepressant in patients with treatment‐resistant depression (TRD) with or without comorbid anxiety.
Comparable studies
Other observational and cohort studies on esketamine for anxiety, most cited first.
Citations in the library
Cited by 31
- Esketamine Nasal Spray versus Quetiapine for Treatment-Resistant Depression New England Journal of Medicine October 4, 2023
- Esketamine Treatment for Depression in Adults: A PRISMA Systematic Review and Meta-Analysis. American Journal of Psychiatry March 1, 2025
- Investigating the Effectiveness and Tolerability of Intranasal Esketamine Among Older Adults With Treatment-Resistant Depression (TRD): A Post-hoc Analysis from the REAL-ESK Study Group American Journal of Geriatric Psychiatry July 8, 2023
- Facts and myths about use of esketamine for treatment-resistant depression: a narrative clinical review. Frontiers in Psychiatry 2024
- Efficacy and acceptability of psilocybin for primary or secondary depression: A systematic review and meta-analysis of randomized controlled trials Frontiers in Psychiatry February 15, 2024
and 26 more in the library
Cites 7
- Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms Pharmacological Reviews June 26, 2018
- Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study American Journal of Psychiatry May 21, 2019
- Measurement of dissociative states with the Clinician‐Administered Dissociative States Scale (CADSS) Journal of Traumatic Stress 1998
- Tripping on nothing: placebo psychedelics and contextual factors Psychopharmacology March 7, 2020
- Effect of Baseline Anxious Depression on Initial and Sustained Antidepressant Response to Ketamine The Journal of Clinical Psychiatry September 25, 2014
and 2 more in the library